 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
An Expanded Access Program For Lenalidomide Plus Dexamethasone In Previously Treated Subjects With Multiple Myeloma
|
|
|
|
Phase IV
|
|
|
|
CC-5013-MM-016
NCT00179647
|
|
| |
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
|
|
|
|
Phase III, Phase II
|
|
|
|
UARK 2003-26
NCT00090493
|
|
| |
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
|
|
|
|
Phase III, Phase II
|
|
|
|
RPCI-I-72806
I 72806, NCT00536601
|
|
| |
In-Vivo Activated T-Cell Depletion to Prevent GVHD
|
|
|
|
Phase III, Phase II
|
|
|
|
0705-20 IUCRO-0196
NCT00594308
|
|
| |
Non-Myeloablative Allogeneic HSCT From HLA Matched Related Donors for the Treatment of Low Grade B Cell Malignancies
|
|
|
|
Phase III, Phase II
|
|
|
|
F080429003
UAB-0775, NCT00714259
|
|
| |
Thalidomide and Prednisone After Autologous Stem Cell Transplantation in
Treating Patients With Multiple Myeloma
|
|
|
|
Phase III
|
|
|
|
CAN-NCIC-MY10
NCT00049673, NCIC-MY.10, CAN-NCIC-JMY10, ECOG-NCIC-JMY10, MY10
|
|
| |
Melphalan and Prednisone With or Without Bortezomib in Treating Older Patients With Newly Diagnosed Multiple Myeloma
|
|
|
|
Phase III
|
|
|
|
UCLA-0409110-01
JJPRD-26866138-MMY-3002, NCT00111319
|
|
| |
Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Multiple Myeloma
|
|
|
|
Phase III
|
|
|
|
CALGB-100104
CALGB-100104, ECOG-CALGB-100104, NCT00114101
|
|
| |
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II or Stage III Multiple Myeloma
|
|
|
|
Phase III
|
|
|
|
FHCRC-2004.00
6004, MEDIMMUNE-FHCRC-2004.00, NCT00217438
|
|
| |
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
|
|
|
|
Phase III
|
|
|
|
MAYO-MC0289
MAYO-IRB-421-03, NCT00432458
|
|
